Literature DB >> 17261617

Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency.

Marco Nevyjel1, Alessandra Pontillo, Lorenzo Calligaris, Alberto Tommasini, Andrea D'Osualdo, Hans R Waterham, Marilena Granzotto, Sergio Crovella, Egidio Barbi, Alessandro Ventura.   

Abstract

Mevalonate kinase deficiency is a rare inborn disorder of isoprenoid and sterol biosynthesis characterized by a recurrent autoinflammatory syndrome and, in most severe cases, psychomotor delay. Clinical manifestations can be very complex and, in some cases, mimic a chronic inflammatory disease. Diagnosis is also complex and often requires immunologic, genetic, and biochemical investigations. There is no standardized therapy, but biological agents could help to control inflammatory complaints in some cases. A severe case of mevalonate kinase deficiency that was associated with nephritis and successfully treated with anakinra (interleukin 1 receptor antagonist) is reported here, and new insights into diagnosis and therapy of this complex disorder are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261617     DOI: 10.1542/peds.2006-2015

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

Review 1.  Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience.

Authors:  Svetlana Kostjukovits; Liisa Kalliokoski; Kaisu Antila; Matti Korppi
Journal:  Eur J Pediatr       Date:  2015-02-27       Impact factor: 3.183

Review 2.  C3 glomerulopathy in NLRP12-related autoinflammatory disorder: case-based review.

Authors:  Özge Başaran; Nermin Uncu; Nilgün Çakar; Eda Tahir Turanlı; Saba Kiremitci; Fatma Aydın; Umut Selda Bayrakcı
Journal:  Rheumatol Int       Date:  2018-06-27       Impact factor: 2.631

3.  Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity.

Authors:  Aashiq H Kachroo; Jon M Laurent; Christopher M Yellman; Austin G Meyer; Claus O Wilke; Edward M Marcotte
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

4.  Anti-interleukin 6 receptor therapy for hyper-IgD syndrome.

Authors:  Anne Musters; Paul Peter Tak; Dominique L P Baeten; Sander W Tas
Journal:  BMJ Case Rep       Date:  2015-10-29

Review 5.  Hyperimmunoglobulin D syndrome in childhood.

Authors:  Jeroen C H van der Hilst; Joost Frenkel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

6.  Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome.

Authors:  Hiba M Shendi; Deirdre Walsh; J David M Edgar
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

Review 7.  Biologics in children's autoimmune disorders: efficacy and safety.

Authors:  Luciana Breda; Marianna Del Torto; Sara De Sanctis; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

Review 8.  The spectrum of autoinflammatory diseases: recent bench to bedside observations.

Authors:  John G Ryan; Raphaela Goldbach-Mansky
Journal:  Curr Opin Rheumatol       Date:  2008-01       Impact factor: 5.006

Review 9.  Monogenic autoinflammatory diseases: concept and clinical manifestations.

Authors:  Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Clin Immunol       Date:  2013-04-09       Impact factor: 3.969

10.  The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.

Authors:  Lorenzo Calligaris; Federico Marchetti; Alberto Tommasini; Alessandro Ventura
Journal:  Eur J Pediatr       Date:  2007-06-23       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.